In-vitro antidiabetic activity of a Bistorta officinalis Delarbre root extract can not be confirmed in the in-vivo models hen's egg test and Drosophila melanogaster.

• DOI: 10.26402/jpp.2023.1.04
• Publication Date: 2023-02-01
• Authors: Inga Bauer; Gerald Rimbach; Sandra Nevermann; Cathrina Neuhauser; Bettina Schwarzinger; Clemens Schwarzinger; Julian Weghuber; Kai Lüersen
• Keywords: Acarbose

The potential of plant bioactives for the prevention and therapy diabetes is increasingly being recognized. In present study we investigated antidiabetic properties an aqueous Bistorta officinalis Delarbre extract (BODE) by employing both in-vitro assays in-vivo models. Multiple targets in glucose homeostasis which are involved regulation blood level were affected BODE in-vitro. exhibited inhibitory activities towards intestinal carbohydrate-hydrolysing enzymes α-amylase α-glucosidase with IC50 values 81.5 μg/mL 8.4 μg/mL, respectively. Furthermore, moderate reduction dipeptidyl peptidase-4 (DPP4) enzyme activity was evident when tested presence 1.0 mg/mL BODE. A significant inhibition transporter sodium-dependent 1 (SGLT1) response to shown Caco-2 cells mounted Ussing chambers. High performance liquid chromatography-mass spectrometry analyses revealed several including gallotannins, catechins chlorogenic acid. Although our data promising, BODE-supplementation model organism Drosophila melanogaster lacked confirm effect in-vivo. Moreover, failed reduce levels chicken embryos (in-ovo). Hence, probably not a suitable candidate developing pharmaceutical against mellitus.